US FDA accepts Pfizer's axitinib filing in renal cell carcinoma
This article was originally published in Scrip
Executive Summary
The US FDA has accepted Pfizer's filing of axitinib for patients with advanced renal cell carcinoma (RCC). This submission was based on Phase III data from the AXIS 1032 trial, comparing axitinib with sorafenib in patients with previously treated advanced RCC, which Pfizer presented at the recent ASCO meeting.